Beyond Antioxidant Activity: Redox-Inflammatory Network Modulation as a Framework for the Multi-Organ Pharmacology of Moringa oleifera.

Abstract

Moringa oleifera (M. oleifera) is a multipurpose medicinal plant with over 160 catalogued bioactive compounds and reported activity across metabolic, inflammatory, infectious, and neoplastic diseases, yet its pharmacology has remained mechanistically fragmented, limiting translational interpretation. In this narrative review, we synthesize evidence from in silico analyses, cellular systems, animal models, and human studies to evaluate whether structurally diverse phytochemicals-including glucosinolates, isothiocyanates, flavonoids, and phenolic acids-converge on interconnected redox and inflammatory regulatory networks centered on NF-κB and Nrf2/Keap1 signaling, offering a plausible systems-level explanation for their coordinated effects on immune function, oxidative stress, and metabolic homeostasis. Preclinical evidence for this convergence is extensive and consistent, with documented effects on inflammatory signaling, oxidative stress regulation, and cell fate determination relevant to hepatoprotection, cardiometabolic regulation, neuroprotection, and tumor biology. Clinical evidence, by contrast, is considerably more limited: available trials report modest and inconsistent benefits for glycemic control, cardiovascular parameters, and immune-related outcomes, constrained by heterogeneous phytochemical composition, minimal pharmacokinetic characterization, and variable extraction and formulation methods. Safety data indicate general tolerability at commonly used doses, though reproductive effects and herb-drug interactions remain incompletely defined. Collectively, current evidence positions M. oleifera as a mechanistically plausible, multi-target modulator of redox and inflammatory networks rather than a validated therapeutic agent; realizing its clinical potential will require standardized preparations, rigorous pharmacokinetic profiling, biomarker-anchored trial design, and evaluation in well-powered controlled trials.